Login Register Cart 0
Review Article

青光眼治疗引起的泪膜，结膜和角膜修饰

卷 26, 期 22, 2019

页: [4253 - 4261] 页: 9

弟呕挨: 10.2174/0929867326666190517111823

价格: $65

摘要

眼表疾病的特征在于泪膜不稳定性以及眼表的组织病理学和临床变化。 青光眼患者经常患有长期使用保留的药物以降低眼内压而引起的眼表疾病。 苯扎氯铵是青光眼药物中最常用的防腐剂。 本微型书讨论了其对泪膜，结膜和角膜的影响以及对青光眼治疗的影响。

关键词: 青光眼，防腐剂，苯扎氯铵，眼表疾病，角膜修饰，泪膜。

« Previous Next »
[1]
The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop. Ocul. Surf., 2007, 5(2), 75-92.
[http://dx.doi.org/10.1016/S1542-0124(12)70081-2] [PMID: 17508116]
[2]
European Glaucoma Society. Terminology and Guidelines for glaucoma, 2014.
[3]
Trzeciecka, A.; Paterno, J.J.; Toropainen, E.; Koskela, A.; Podracka, L.; Korhonen, E.; Kauppinen, A.; Kaarniranta, K.; Smedowski, A. Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa. Eur. J. Pharmacol., 2016, 788, 12-20.
[http://dx.doi.org/10.1016/j.ejphar.2016.06.014] [PMID: 27288881]
[4]
Leung, E.W.; Medeiros, F.A.; Weinreb, R.N. Prevalence of ocular surface disease in glaucoma patients. J. Glaucoma, 2008, 17(5), 350-355.
[http://dx.doi.org/10.1097/IJG.0b013e31815c5f4f] [PMID: 18703943]
[5]
Garcia-Feijoo, J.; Sampaolesi, J.R. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin. Ophthalmol., 2012, 6, 441-446.
[PMID: 22536034]
[6]
Anwar, Z.; Wellik, S.R.; Galor, A. Glaucoma therapy and ocular surface disease: current literature and recommendations. Curr. Opin. Ophthalmol., 2013, 24(2), 136-143.
[http://dx.doi.org/10.1097/ICU.0b013e32835c8aba] [PMID: 23542350]
[7]
Baudouin, C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol., 2008, 86(7), 716-726.
[http://dx.doi.org/10.1111/j.1755-3768.2008.01250.x] [PMID: 18537937]
[8]
Baudouin, C.; Liang, H.; Hamard, P.; Riancho, L.; Creuzot-Garcher, C.; Warnet, J.M.; Brignole-Baudouin, F. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology, 2008, 115(1), 109-115.
[http://dx.doi.org/10.1016/j.ophtha.2007.01.036] [PMID: 17532048]
[9]
Pisella, P.J.; Pouliquen, P.; Baudouin, C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br. J. Ophthalmol., 2002, 86(4), 418-423.
[http://dx.doi.org/10.1136/bjo.86.4.418] [PMID: 11914211]
[10]
Mastropasqua, L.; Agnifili, L.; Mastropasqua, R.; Fasanella, V.; Nubile, M.; Toto, L.; Carpineto, P.; Ciancaglini, M. In vivo laser scanning confocal microscopy of the ocular surface in glaucoma. Microsc. Microanal., 2014, 20(3), 879-894.
[http://dx.doi.org/10.1017/S1431927614000324] [PMID: 24576766]
[11]
Rossi, G.C.; Pasinetti, G.M.; Scudeller, L.; Bianchi, P.E. Ocular surface disease and glaucoma: how to evaluate impact on quality of life. J. Ocul. Pharmacol. Ther., 2013, 29(4), 390-394.
[http://dx.doi.org/10.1089/jop.2011.0159] [PMID: 23215770]
[12]
Broadway, D.C.; Grierson, I.; O’Brien, C.; Hitchings, R.A. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch. Ophthalmol., 1994, 112(11), 1446-1454.
[http://dx.doi.org/10.1001/archopht.1994.01090230060021] [PMID: 7980134]
[13]
Baudouin, C.; Labbé, A.; Liang, H.; Pauly, A.; Brignole-Baudouin, F. Preservatives in eyedrops: the good, the bad and the ugly. Prog. Retin. Eye Res., 2010, 29(4), 312-334.
[http://dx.doi.org/10.1016/j.preteyeres.2010.03.001] [PMID: 20302969]
[14]
Burstein, N.L.; Klyce, S.D. Electrophysiologic and morphologic effects of ophthalmic preparations on rabbit cornea epithelium. Invest. Ophthalmol. Vis. Sci., 1977, 16(10), 899-911.
[PMID: 908644]
[15]
Friedlaender, M.H.; Breshears, D.; Amoozgar, B.; Sheardown, H.; Senchyna, M. The dilution of benzalkonium chloride (BAK) in the tear film. Adv. Ther., 2006, 23(6), 835-841.
[http://dx.doi.org/10.1007/BF02850204] [PMID: 17276951]
[16]
Champeau, E.; Edelhauser, H. Effect of ophthalmic preservatives on the ocular surface: conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconate., 1986.
[17]
Noecker, R. Effects of common ophthalmic preservatives on ocular health. Adv. Ther., 2001, 18(5), 205-215.
[http://dx.doi.org/10.1007/BF02853166] [PMID: 11783457]
[18]
De Saint Jean, M.; Debbasch, C.; Brignole, F.; Rat, P.; Warnet, J.M.; Baudouin, C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr. Eye Res., 2000, 20(2), 85-94.
[http://dx.doi.org/10.1076/0271-3683(200002)2021-DFT085] [PMID: 10617908]
[19]
Doughty, M.J.; Bergmanson, J.P.G. New insights into the surface cells and glands of the conjunctiva and their relevance to the tear film. Optometry, 2003, 74(8), 485-500.
[PMID: 12926821]
[20]
Pauly, A.; Brignole-Baudouin, F.; Labbé, A.; Liang, H.; Warnet, J.M.; Baudouin, C. New tools for the evaluation of toxic ocular surface changes in the rat. Invest. Ophthalmol. Vis. Sci., 2007, 48(12), 5473-5483.
[http://dx.doi.org/10.1167/iovs.06-0728] [PMID: 18055795]
[21]
Herreras, J.M.; Pastor, J.C.; Calonge, M.; Asensio, V.M. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology, 1992, 99(7), 1082-1088.
[http://dx.doi.org/10.1016/S0161-6420(92)31847-0] [PMID: 1495787]
[22]
Ruangvaravate, N.; Prabhasawat, P.; Vachirasakchai, V.; Tantimala, R. High Prevalence of Ocular Surface Disease Among Glaucoma Patients in Thailand. J. Ocul. Pharmacol. Ther., 2018, 34(5), 387-394.
[http://dx.doi.org/10.1089/jop.2017.0104] [PMID: 29596033]
[23]
Malvitte, L.; Montange, T.; Vejux, A.; Baudouin, C.; Bron, A.M.; Creuzot-Garcher, C.; Lizard, G. Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs. Br. J. Ophthalmol., 2007, 91(1), 29-32.
[http://dx.doi.org/10.1136/bjo.2006.101485] [PMID: 16943231]
[24]
Hommer, A.; Schmidl, D.; Kromus, M.; Bata, A.M.; Fondi, K.; Werkmeister, R.M.; Baar, C.; Schmetterer, L.; Garhöfer, G. Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness. Eur. J. Ophthalmol., 2018, 28(4), 385-392.
[http://dx.doi.org/10.1177/1120672117753703] [PMID: 29592773]
[25]
Ciancaglini, M.; Carpineto, P.; Agnifili, L.; Nubile, M.; Fasanella, V.; Mastropasqua, L. Conjunctival modifications in ocular hypertension and primary open angle glaucoma: an in vivo confocal microscopy study. Invest. Ophthalmol. Vis. Sci., 2008, 49(7), 3042-3048.
[http://dx.doi.org/10.1167/iovs.07-1201] [PMID: 18316705]
[26]
Mastropasqua, L.; Agnifili, L.; Mastropasqua, R.; Fasanella, V. Conjunctival modifications induced by medical and surgical therapies in patients with glaucoma. Curr. Opin. Pharmacol., 2013, 13(1), 56-64.
[http://dx.doi.org/10.1016/j.coph.2012.10.002] [PMID: 23127698]
[27]
Pisella, P.J.; Debbasch, C.; Hamard, P.; Creuzot-Garcher, C.; Rat, P.; Brignole, F.; Baudouin, C. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest. Ophthalmol. Vis. Sci., 2004, 45(5), 1360-1368.
[http://dx.doi.org/10.1167/iovs.03-1067] [PMID: 15111589]
[28]
Lewis, R.A.; Katz, G.J.; Weiss, M.J.; Landry, T.A.; Dickerson, J.E.; James, J.E.; Hua, S.Y.; Sullivan, E.K.; Montgomery, D.B.; Wells, D.T.; Bergamini, M.V. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J. Glaucoma, 2007, 16(1), 98-103.
[http://dx.doi.org/10.1097/01.ijg.0000212274.50229.c6] [PMID: 17224758]
[29]
Hong, S.; Lee, C.S.; Seo, K.Y.; Seong, G.J.; Hong, Y.J. Effects of topical antiglaucoma application on conjunctival impression cytology specimens. Am. J. Ophthalmol., 2006, 142(1), 185-186.
[http://dx.doi.org/10.1016/j.ajo.2006.02.056] [PMID: 16815281]
[30]
Ciancaglini, M.; Carpineto, P.; Agnifili, L.; Nubile, M.; Fasanella, V.; Lanzini, M.; Calienno, R.; Mastropasqua, L. An in vivo confocal microscopy and impression cytology analysis of preserved and unpreserved levobunolol-induced conjunctival changes. Eur. J. Ophthalmol., 2008, 18(3), 400-407.
[http://dx.doi.org/10.1177/112067210801800314] [PMID: 18465723]
[31]
Mastropasqua, R.; Agnifili, L.; Fasanella, V.; Nubile, M.; Gnama, A.A.; Falconio, G.; Perri, P.; Di Staso, S.; Mariotti, C. The conjunctiva-associated lymphoid tissue in chronic ocular surface diseases. Microsc. Microanal., 2017, 23(4), 697-707.
[http://dx.doi.org/10.1017/S1431927617000538] [PMID: 28480834]
[32]
Mastropasqua, L.; Agnifili, L.; Fasanella, V.; Curcio, C.; Ciabattoni, C.; Mastropasqua, R.; Toto, L.; Ciancaglini, M. Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study. Acta Ophthalmol., 2013, 91(5), e397-e405.
[http://dx.doi.org/10.1111/aos.12131] [PMID: 23601909]
[33]
Uusitalo, H.; Egorov, E.; Kaarniranta, K.; Astakhov, Y.; Ropo, A. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. Clin. Ophthalmol., 2016, 10, 445-454.
[http://dx.doi.org/10.2147/OPTH.S91402] [PMID: 27041987]
[34]
Baudouin, C.; Garcher, C.; Haouat, N.; Bron, A.; Gastaud, P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology, 1994, 101(3), 454-460.
[http://dx.doi.org/10.1016/S0161-6420(94)31322-4] [PMID: 7907416]
[35]
Sherwood, M.B.; Grierson, I.; Millar, L.; Hitchings, R.A. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology, 1989, 96(3), 327-335.
[http://dx.doi.org/10.1016/S0161-6420(89)32888-0] [PMID: 2710524]
[36]
Thorne, J.E.; Anhalt, G.J.; Jabs, D.A. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology, 2004, 111(1), 45-52.
[http://dx.doi.org/10.1016/j.ophtha.2003.03.001] [PMID: 14711713]
[37]
Mastropasqua, R.; Fasanella, V.; Brescia, L.; Oddone, F.; Mariotti, C.; Di Staso, S.; Agnifili, L. In Vivo confocal imaging of the conjunctiva as a predictive tool for the glaucoma filtration surgery outcome. Invest. Ophthalmol. Vis. Sci., 2017, 58(6), BIO114-BIO120.
[http://dx.doi.org/10.1167/iovs.17-21795] [PMID: 28586797]
[38]
Baudouin, C. Ocular surface and external filtration surgery: mutual relationships. Dev. Ophthalmol., 2017, 59, 67-79.
[http://dx.doi.org/10.1159/000458487] [PMID: 28442688]
[39]
Inoue, K.; Okugawa, K.; Kato, S.; Inoue, Y.; Tomita, G.; Oshika, T.; Amano, S. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. J. Glaucoma, 2003, 12(6), 480-485.
[http://dx.doi.org/10.1097/00061198-200312000-00007] [PMID: 14646683]
[40]
Noecker, R.J.; Herrygers, L.A.; Anwaruddin, R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea, 2004, 23(5), 490-496.
[http://dx.doi.org/10.1097/01.ico.0000116526.57227.82] [PMID: 15220734]
[41]
Pérez-Bartolomé, F.; Martínez-de-la-Casa, J.M.; Arriola-Villalobos, P.; Fernández-Pérez, C.; Polo, V.; García-Feijoó, J. Ocular surface disease in patients under topical treatment for glaucoma. Eur. J. Ophthalmol., 2017, 27(6), 694-704.
[http://dx.doi.org/10.5301/ejo.5000977] [PMID: 28497458]
[42]
Martone, G.; Frezzotti, P.; Tosi, G.M.; Traversi, C.; Mittica, V.; Malandrini, A.; Pichierri, P.; Balestrazzi, A.; Motolese, P.A.; Motolese, I.; Motolese, E. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am. J. Ophthalmol., 2009, 147(4), 725-735.e1.
[http://dx.doi.org/10.1016/j.ajo.2008.10.019] [PMID: 19181302]
[43]
Ranno, S.; Fogagnolo, P.; Rossetti, L.; Orzalesi, N.; Nucci, P. Changes in corneal parameters at confocal microscopy in treated glaucoma patients. Clin. Ophthalmol., 2011, 5, 1037-1042.
[http://dx.doi.org/10.2147/OPTH.S22874] [PMID: 21845031]
[44]
Rossi, G.C.; Blini, M.; Scudeller, L.; Ricciardelli, G.; Depolo, L.; Amisano, A.; Bossolesi, L.; Pasinetti, G.M.; Bianchi, P.E. Effect of preservative-free tafluprost on keratocytes, sub-basal nerves, and endothelium: a single-blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group. J. Ocul. Pharmacol. Ther., 2013, 29(9), 821-825.
[http://dx.doi.org/10.1089/jop.2013.0069] [PMID: 23944905]
[45]
Rahmatnejad, K.; Rapuano, C.J.; Ichhpujani, P.; Wizov, S.S.; Moster, M.R.; Hark, L.A.; Katz, J. The effects of latanoprost with benzalkonium chloride versus travoprost with sofzia on the ocular surface. Eye Contact Lens, 2017, 0, 1-6.
[PMID: 28617732]
[46]
Peace, J.H.; Ahlberg, P.; Wagner, M.; Lim, J.M.; Wirta, D.; Branch, J.D. Polyquaternium-1-preserved travoprost 0.003% or benzalkonium chloride-preserved travoprost 0.004% for glaucoma and ocular hypertension. Am. J. Ophthalmol., 2015, 160(2), 266-274.e1.
[http://dx.doi.org/10.1016/j.ajo.2015.04.041] [PMID: 25935098]
[47]
Jayanthi, C.R.; Divyashree, R.N.; Sujatha, B.L. Efficacy and safety of topical BAK-free travoprost 0.004% versus BAK-preserved travoprost 0.004% in the treatment of primary open angle glaucoma: a comparative study at a tertiary care hospital. Int. J. Basic Clin. Pharmacol., 2017, 6, 2199-2205.
[http://dx.doi.org/10.18203/2319-2003.ijbcp20173744]
[48]
Ammar, D.A.; Noecker, R.J.; Kahook, M.Y. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv. Ther., 2010, 27(11), 837-845.
[http://dx.doi.org/10.1007/s12325-010-0070-1] [PMID: 20931366]
[49]
Noecker, R.; Miller, K.V. Benzalkonium chloride in glaucoma medications. Ocul. Surf., 2011, 9(3), 159-162.
[http://dx.doi.org/10.1016/S1542-0124(11)70025-8] [PMID: 21791190]
[50]
Steven, D.W.; Alaghband, P.; Lim, K.S. Preservatives in glaucoma medication. Br. J. Ophthalmol., 2018, 102(11), 1497-1503.
[http://dx.doi.org/10.1136/bjophthalmol-2017-311544] [PMID: 29973365]
[51]
Gómez-Aguayo, F.; Paczka, J.A.; Leñero-Córdova, R.; Jiménez-Román, J.; Davila-Villarreal, J.; Hartleben, C.; Baiza-Durán, L.; Olvera-Montaño, O.; García-Velez, F.; Muñoz-Villegas, P. A phase III randomized clinical trial of a 0.5% timolol+0.2% brimonidine+2.0% dorzolamide fixed combination, preservative-free ophthalmic solution vs. 0.5% timolol+0.2% brimonidine+2.0% dorzolamide fixed combination in patients with controlled primary open-angle glaucoma. Ophthalmol. Ther., 2018, 7(1), 145-156.
[http://dx.doi.org/10.1007/s40123-018-0128-8] [PMID: 29680880]

Rights & Permissions Print Cite
Article Metrics
46
4
1
© 2024 Bentham Science Publishers | Privacy Policy